All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-06-18T19:19:05.000Z

Simon Rule | EHA 2018 | What are the key findings of the acalabrutinib study in patients with WM?

By Simon Rule, Elina Simanovits
Featured
Simon Rule
Jun 18, 2018
Share:

Bookmark this article

23rd Congress of the European Hematology Association, 14-17 June 2018, Stockholm, Sweden
Simon Rule
Derriford Hospital, Plymouth Hospitals NHS Trust, Plymouth, UK

Interview topic: What are the key findings of the acalabrutinib study in patients with WM?

Simon Rule | EHA 2018 | What are the key findings of the acalabrutinib study in patients with WM?

More about...
AcalabrutinibEHA 2018Indolent B-cell lymphomasWaldenström’s macroglobulinemia

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Lymphoma Hub Satellite Symposium 2019 | Chemo-free approaches in MCL - Professor Simon Rule

Professor Simon Rule discussed the novel chemotherapy-free treatment approaches in MCL during the Lymphoma Hub Satellite Symposium at 15-ICML.

Jul 26, 2019
Add bookmark

Lymphoma Hub Satellite Symposium 2019 | Chemo-free approaches in MCL - Professor Simon Rule

Professor Simon Rule discussed the novel chemotherapy-free treatment approaches in MCL during the Lymphoma...

Jul 26, 2019
Add bookmark

ICML 2019: what are the latest advances in the treatment of MCL?

ICML 2019: what are the latest advances in the treatment of MCL?

Jun 24, 2019
Add bookmark

ICML 2019: what are the latest advances in the treatment of MCL?

ICML 2019: what are the latest advances in the treatment of MCL?

Jun 24, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox